Who Owns MAIA Biotechnology Stock?
NYSE: MAIAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 11:17 AM ET
Ownership breakdown
- Held by institutions
- 21.91%
- Held by insiders
- 14.41%
- Institutional holders
- 38
- Institutions 21.9%
- Insiders 14.4%
- Public and other 63.7%
Who owns MAIA Biotechnology stock?
Institutional investors own about 21.9% of MAIA Biotechnology's shares, spread across 38 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 14.41% of MAIA.
The largest institutional holders are Solas Capital Management, LLC (4.91%), Alyeska Investment Group, L.p. (4.05%) and Vanguard Capital Management LLC (3.91%). Together, the top 10 institutions control 19.7% of shares outstanding. In their latest filings, 4 of the top 10 institutions increased their MAIA positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of MAIA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Solas Capital Management, LLC | 3.03M | 4.91% | -29.5% |
| Alyeska Investment Group, L.p. | 2.50M | 4.05% | 0.0% |
| Vanguard Capital Management LLC | 2.41M | 3.91% | +16.4% |
| 683 Capital Management LLC | 1.07M | 1.73% | 0.0% |
| Centric Wealth Management | 796.72K | 1.29% | 0.0% |
| Cable Car Capital, LP | 514.58K | 0.83% | -20.6% |
| Geode Capital Management, LLC | 504.38K | 0.82% | +39.9% |
| Bleichroeder LP | 500.00K | 0.81% | 0.0% |
| Renaissance Technologies, LLC | 415.70K | 0.67% | +100.0% |
| Blackrock Inc. | 403.01K | 0.65% | +214.9% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of MAIA
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.68M | 2.72% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 668.12K | 1.08% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 288.37K | 0.47% |
| iShares Trust-iShares Micro-Cap ETF | 177.69K | 0.29% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 73.03K | 0.12% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 69.78K | 0.11% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 39.71K | 0.06% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 28.59K | 0.05% |
| EQ Advisors Trust-1290 VT Micro Cap Portfolio | 12.03K | 0.02% |
Frequently asked questions
Who is the largest shareholder of MAIA Biotechnology?
Solas Capital Management, LLC is the largest institutional shareholder of MAIA, owning 4.91% of shares outstanding (3.03M shares) as of its latest 13F filing.
What percentage of MAIA Biotechnology is owned by institutions?
Institutions own about 21.9% of MAIA shares and 25.6% of the public float.
How much of MAIA Biotechnology do insiders own?
Insiders, such as officers and directors, own about 14.41% of MAIA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.